All In Biotech

Drug Trial Radar · NCT07244393

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

A Phase 1 Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Lutetium (177Lu) DGUL in Combination With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (IGNITE Trial)

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 29, 2026

Primary completion

Apr 2029

Study completion Apr 2029

Sponsor

Lead sponsor
Cellbion Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy. Participants will: Monotherapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals Combination therapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals along with pembrolizumab up to 18 times at 6-week intervals

Conditions

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

  • Lutetium (177Lu) DGULDrug

    Lutetium (177Lu) DGUL will be administered in 4 doses at 6-week intervals (Q6W), and for patients showing good tolerance, additional 2 doses may be added, for a maximum of 6 doses.

  • PembrolizumabDrug

    pembrolizumab will be introduced at a dose of 400 mg every 6 weeks, beginning with the second cycle of Lutetium (177Lu) DGUL, and will continue for up to approximately 2 years (18 doses).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with treatment-emergent adverse events (TEAEs)Time frame: From enrollment to 6-month follow-up after the end of treatment
  2. Number of patients with drug-related TEAEsTime frame: From enrollment to 6-month follow-up after the end of treatment
  3. Adverse events (AEs)Time frame: From enrollment to 6-month follow-up after the end of treatment
  4. Drug-related adverse reactions based on dose limited toxicity (DLT) definitionsTime frame: From enrollment to 6-month follow-up after the end of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.